AR015310A1 - NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES - Google Patents
NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USESInfo
- Publication number
- AR015310A1 AR015310A1 ARP990102703A ARP990102703A AR015310A1 AR 015310 A1 AR015310 A1 AR 015310A1 AR P990102703 A ARP990102703 A AR P990102703A AR P990102703 A ARP990102703 A AR P990102703A AR 015310 A1 AR015310 A1 AR 015310A1
- Authority
- AR
- Argentina
- Prior art keywords
- channels
- compounds
- binders
- relates
- present
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Furan Compounds (AREA)
Abstract
La presente invencion se relaciona con nuevos compuestos multienlazantes que se enlazan a los canales de potasio (K+) y modulan su actividad. Loscompuestos de esta invencion comprenden ligantes de los canales 2-10 K+, covalentemente conectados por un enlazante o enlazantes, donde los ligantes ensu estado monovalente (p.e., no ligados) se enlazan y son capaces de modular la actividad de uno o más tipos de canales K+. La manera de enlazarse los ligantesen conjunto es tal que los agentesmultienlazantes así formados demuestran un efecto biologico y/o terapéutico incrementado, al ser comparado con el mismonumero de ligantes no enlazados puestos a disposicion por el enlace al canal K+. La invencion también se relaciona a los métodos de uso de tales compuestosy a los métodos de preparacion. Los compuestos de esta invencion son particularmente utiles en el tratamiento de enfermedades y condiciones demamíferos que son mediadas por los canales K+. Por consiguiente, lapresente invencion se relaciona también a composiciones farmacéuticas que comprenden unexcipiente aceptable farmacéuticamente y a una cantidad efectiva del compuesto de la presente invencion.The present invention relates to new multi-linker compounds that bind to potassium (K +) channels and modulate their activity. The compounds of this invention comprise binders of the 2-10 K + channels, covalently connected by a linker or linkers, where the binders in their monovalent state (eg, unlinked) are linked and are capable of modulating the activity of one or more types of channels K +. The way of binding the binders together is such that the multi-linking agents thus formed demonstrate an increased biological and / or therapeutic effect, when compared with the same number of unbound binders made available by the link to the K + channel. The invention also relates to the methods of use of such compounds and to the methods of preparation. The compounds of this invention are particularly useful in the treatment of diseases and conditions of mammals that are mediated by the K + channels. Accordingly, the present invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of the compound of the present invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8846598P | 1998-06-08 | 1998-06-08 | |
US9306898P | 1998-07-16 | 1998-07-16 | |
US11386498P | 1998-12-24 | 1998-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015310A1 true AR015310A1 (en) | 2001-04-18 |
Family
ID=27375970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990102703A AR015310A1 (en) | 1998-06-08 | 1999-06-08 | NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1086063A1 (en) |
JP (1) | JP2002517466A (en) |
AR (1) | AR015310A1 (en) |
AU (1) | AU4426499A (en) |
CA (1) | CA2318745A1 (en) |
SG (1) | SG80037A1 (en) |
WO (1) | WO1999064050A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10019067C1 (en) * | 2000-04-18 | 2001-10-04 | Lohmann Therapie Syst Lts | Transdermal plaster comprising dofetilide, is useful for treatment of cardiovascular disorders |
BR0114272A (en) * | 2000-09-29 | 2003-08-26 | Solvay Pharm Bv | Ionic force independent prolonged release pharmaceutical formulation |
WO2002057792A2 (en) * | 2000-12-29 | 2002-07-25 | Neogenesis Pharmaceuticals, Inc. | Affinity selection-based screening of hydrophobic proteins |
WO2008112287A1 (en) * | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
KR20100135909A (en) | 2008-04-17 | 2010-12-27 | 사노피-아벤티스 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0510132B1 (en) * | 1990-09-28 | 1997-05-14 | Neorx Corporation | Polymeric carriers for release of covalently linked agents |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
-
1999
- 1999-06-07 JP JP2000553118A patent/JP2002517466A/en not_active Withdrawn
- 1999-06-07 EP EP99927330A patent/EP1086063A1/en not_active Withdrawn
- 1999-06-07 CA CA002318745A patent/CA2318745A1/en not_active Abandoned
- 1999-06-07 AU AU44264/99A patent/AU4426499A/en not_active Abandoned
- 1999-06-07 WO PCT/US1999/012777 patent/WO1999064050A1/en not_active Application Discontinuation
- 1999-06-08 AR ARP990102703A patent/AR015310A1/en unknown
- 1999-06-08 SG SG9902714A patent/SG80037A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1999064050A9 (en) | 2000-04-20 |
EP1086063A4 (en) | 2001-03-28 |
AU4426499A (en) | 1999-12-30 |
CA2318745A1 (en) | 1999-12-16 |
WO1999064050A8 (en) | 2000-02-24 |
WO1999064050A1 (en) | 1999-12-16 |
SG80037A1 (en) | 2001-04-17 |
EP1086063A1 (en) | 2001-03-28 |
JP2002517466A (en) | 2002-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9879A (en) | CCR5 MODULATORS (APPLICATION DIVISIONAL N ° 6392) | |
DE69737867D1 (en) | TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER | |
NO20026255L (en) | Polymeric micelle compositions | |
MX9300298A (en) | TIOETER CONJUGATES AND PROCEDURE FOR THEIR PREPARATION | |
DK1242401T3 (en) | Cytotoxic agents comprising taxanes and their therapeutic use | |
BR9905977A (en) | Ccr5 modulators | |
TR200001840T2 (en) | Aryl-bound azopolyclic compounds | |
ECSP056256A (en) | TRICYCLE DELTA-OPIOID MODULATORS | |
ES2168737T3 (en) | INHIBITORS OF NITRICO SINTASA OXIDE. | |
AR010752A1 (en) | COMPOUNDS WHICH BIND TO AND ACTIVATE A THROMBOPOYETINE RECEPTOR; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, THEIR USE FOR THE PREPARATION OF MEDICINES, AND PROCESS TO PREPARE SUCH COMPOSITION. | |
HN1999000080A (en) | ISOTIAZOL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. | |
DE60031793D1 (en) | DOXORUBICIN AND DAUNORUBICIN-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE | |
GT199700079A (en) | TRICYCLES DERIVATIVES REPLACED WITH PHENYLAMINE | |
BR0010700A (en) | Analog conjugates of polyamine and quinone conjugates as therapies for cancers and prostate diseases | |
PA8582701A1 (en) | NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF) | |
ES2165723T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCINE. | |
GT199800106A (en) | AZETIDINS. | |
AR015310A1 (en) | NEW DRUGS FROM THE POTASSIUM CHANNEL AND ITS USES | |
PL346019A1 (en) | Nimesulide containing topical pharmaceutical compositions | |
BR0112807A (en) | Indole derivatives and their application as a medicine | |
UY26877A1 (en) | PIRAZOL-TIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, AND ITS INSTRUCTIONS FOR INHIBITING CYCLINE-DEPENDENT KINASES | |
ECSP993000A (en) | NEW DRUGS OF THE POTASSIUM CHANNEL AND ITS USES | |
ATE331730T1 (en) | NEW DEPSIPEPTIDE COMPOUND | |
ES2161913T3 (en) | TRINUCLEAR CATIONIC COMPLEXES OF PLATINO THAT HAVE AN ANTITUMORAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
ECSP993298A (en) | CCR5 MODULATORS |